Intravenous buspirone for the prevention of postoperative nausea and vomiting Peter KrankeKerstin D. RöhmMartin R. Tramèr Clinical Trial 01 May 2012 Pages: 1465 - 1472
Relative bioavailability and pharmacodynamic effects of methantheline compared with atropine in healthy subjects Christian MüllerJörn LötschWerner Siegmund Clinical Trial 21 April 2012 Pages: 1473 - 1481
Pharmacogenetics and healthcare outcomes in patients with chronic heart failure Kye-Min KimMichael D. MurrayDavid A. Flockhart Pharmacogenetics 29 April 2012 Pages: 1483 - 1491
Association of UDP-glucuronosyltransferase 1A9 polymorphisms with adverse reactions to catechol-O-methyltransferase inhibitors in Parkinson’s disease patients Marco FerrariEmilia MartignoniMarco Cosentino Pharmacogenetics 15 April 2012 Pages: 1493 - 1499
Pharmacokinetics of the novel PAR-1 antagonist vorapaxar in patients with hepatic impairment Paul StatkevichTeddy KosoglouDavid L. Cutler Pharmacokinetics and Disposition 19 April 2012 Pages: 1501 - 1508
Vorapaxar, an oral PAR-1 receptor antagonist, does not affect the pharmacokinetics and pharmacodynamics of warfarin Teddy KosoglouYali ZhuDavid L. Cutler Pharmacokinetics and Disposition 05 April 2012 Pages: 1509 - 1516
Population pharmacokinetics and Bayesian estimation of cyclosporine in a Tunisian population of hematopoietic stem cell transplant recipient Hanene EljebariEmna GaiesAnis Klouz Pharmacokinetics and Disposition 15 April 2012 Pages: 1517 - 1524
Exposure to medicines among patients admitted for hip fracture and the case-fatality rate at 1 year: a longitudinal study A. AgustíE. PagèsJ.-R. Laporte Pharmacoepidemiology and Prescription 15 April 2012 Pages: 1525 - 1531
Non-steroidal anti-inflammatory drugs (NSAIDs) and hypertension treatment intensification: a population-based cohort study Jean-Pascal FournierAgnès SommetJean-Louis Montastruc Pharmacoepidemiology and Prescription 15 April 2012 Pages: 1533 - 1540
Paracetamol toxicity: what would be the implications of a change in UK treatment guidelines? David J. McQuadePaul I. DarganDavid M. Wood Pharmacoepidemiology and Prescription 19 April 2012 Pages: 1541 - 1547
Comparison of the effect of mesalazine and sulfasalazine on laboratory parameters: a retrospective observational study Hideki MasudaYasuo TakahashiSatoshi Asai Pharmacoepidemiology and Prescription 01 May 2012 Pages: 1549 - 1555
Bleeding adverse drug reactions (ADRs) in patients exposed to antiplatelet plus serotonin reuptake inhibitor drugs: analysis of the French Spontaneous Reporting Database for a controversial ADR Franck MaschinoCaroline Hurault-DelarueFrench Association of Regional Pharmacovigilance Centers Short Communication 15 April 2012 Pages: 1557 - 1560
CYP2C19 genetics in fatal carisoprodol intoxications Gudrun HøisethUmair MajidEspen Molden Short Communication 15 April 2012 Pages: 1561 - 1565
The effect of lersivirine, a next-generation NNRTI, on the pharmacokinetics of midazolam and oral contraceptives in healthy subjects John DavisGrant LangdonManoli Vourvahis Short Communication 22 April 2012 Pages: 1567 - 1572
Author reply to Fujimi et al Richard A. LarsonOphelia Q. P. Yin Letter to the Editors 04 April 2012 Pages: 1573 - 1574
Bile acid is important for gastrointestinal absorption of nilotinib Akihito FujimiNaoto TakahashiKenichi Sawada Letter to the Editors 15 April 2012 Pages: 1575 - 1576